Company Description
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for gastrointestinal diseases.
The company develops its products based on vonozopran, an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Its products under development include VOQUEZNA, which has completed its Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and its Phase II clinical trials for the as-needed dosing for active heartburn episodes; and VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which have completed the Phase III clinical trials for the eradication of Helicobacter pylori infection.
The company has the rights in the United States, Europe, and Canada for P-CAB. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 427 |
| CEO | Steven Basta |
Contact Details
Address: 100 Campus Drive, Suite 102 Florham Park, New Jersey 07932 United States | |
| Phone | 877 742 8466 |
| Website | phathompharma.com |
Stock Details
| Ticker Symbol | PHAT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001783183 |
| CUSIP Number | 71722W107 |
| ISIN Number | US71722W1071 |
| Employer ID | 82-4151574 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven L. Basta M.B.A. | Chief Executive Officer, President and Director |
| David A. Socks | Co-Founder and Director |
| Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder and Chief Operating Officer |
| Molly Henderson CPA, MBA | Chief Financial and Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2025 | 8-K | Current Report |
| Apr 3, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 10-K | Annual Report |
| Dec 11, 2024 | 8-K | Current Report |